Drug Trial Radar · NCT05226598
Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)
Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
739
Actual
Start
Mar 24, 2022
Primary completion
Sep 24, 2024
Study completion Jan 9, 2026
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Feb 7, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary hypothesis is that pembrolizumab/vibostolimab (MK-7684A) in combination with chemotherapy is superior to pembrolizumab in combination with chemotherapy with respect to overall survival (OS) in participants with programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS) ≥1%.
Conditions
- Metastatic Non-Small Cell Lung Cancer
Interventions
Pembrolizumab/VibostolimabBiological
Co-formulation of pembrolizumab 200 mg/20 mL vial and vibostolimab 200 mg administered as IV infusion for up to 35 administrations
CarboplatinDrug
Carboplatin 10 mg/ml administered as IV infusion Q3W for 4 administrations
CisplatinDrug
Cisplatin 1 mg/ml administered as IV infusion Q3W for 4 administrations
PaclitaxelDrug
Paclitaxel 6mg/ml administered as IV infusion Q3W for 4 administrations
Nab-paclitaxelDrug
Nab-paclitaxel 100 mg/vial administered as IV infusion Days 1, 8, and 15 of each 21-day cycle for 4 administrations
PemetrexedDrug
Pemetrexed 500 mg/vial administered as IV infusion Q3W until progression, intolerable adverse event (AE), or participant or physician decision
PembrolizumabBiological
Pembrolizumab 25 mg/mL administered as IV infusion Q3W for up to 35 administrations
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS) in Participants With Programmed Cell Death-Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥1%Time frame: Up to approximately 29 months
Locations
149 sites in 19 countries. Site status is shown where the registry gives one.
UCHealth Memorial Hospital-Heme Onc ( Site 0003)
Colorado Springs, Colorado
University of Colorado Health - Harmony-Cancer Care and Hematology - Ft. Collins ( Site 0031)
Fort Collins, Colorado
Mayo Clinic in Florida ( Site 0022)
Jacksonville, Florida
Mount Sinai Hospital ( Site 0011)
Chicago, Illinois
University of Chicago Medical Center ( Site 0015)
Chicago, Illinois
New England Cancer Specialists ( Site 0008)
Scarborough, Maine
Cancer and Hematology Centers of Western Michigan ( Site 0002)
Grand Rapids, Michigan
Mayo Clinic in Rochester, Minnesota ( Site 0030)
Rochester, Minnesota
Stony Brook University-Cancer Center ( Site 0013)
Stony Brook, New York
Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0012)
Lancaster, Pennsylvania
Charleston Oncology ( Site 0019)
Charleston, South Carolina
University of Virginia Cancer Center ( Site 0018)
Charlottesville, Virginia
Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0206)
La Rioja, Argentina
Centro de Oncología e Investigación de Buenos Aires ( Site 0203)
Berazategui, Buenos Aires, Argentina
Instituto de Investigaciones Clínicas Mar del Plata ( Site 0204)
Mar del Plata, Buenos Aires, Argentina
Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 0209)
ABB, Buenos Aires F.D., Argentina
Centro de Educación Médica e Investigaciones Clínicas (CEMIC)-Medical Oncology ( Site 0202)
Buenos Aires, Buenos Aires F.D., Argentina
Sanatorio Parque ( Site 0205)
Rosario, Santa Fe Province, Argentina
Hospital Provincial del Centenario ( Site 0212)
Rosario, Santa Fe Province, Argentina
Klinik Floridsdorf-Abteilung für Innere Medizin und Pneumologie ( Site 0701)
Vienna, Austria
Klinik Penzing-2. Lungenabteilung ( Site 0702)
Vienna, State of Vienna, Austria
Medizinische Universität Graz ( Site 0704)
Graz, Styria, Austria
Medizinische Universitaet Innsbruck ( Site 0703)
Innsbruck, Tyrol, Austria
Ordensklinikum Linz GmbH Elisabethinen-Department of Pneumology ( Site 0705)
Linz, Upper Austria, Austria
Kepler Universitätsklinikum ( Site 0707)
Linz, Upper Austria, Austria
Instituto Nacional de Câncer José Alencar Gomes da Silva - INCA ( Site 0406)
Rio de Janeiro, Brazil
Hospital Paulistano ( Site 0401)
São Paulo, Brazil
Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 0403)
Natal, Rio Grande do Norte, Brazil
Hospital Nossa Senhora da Conceição-Centro Integrado de Pesquisa em Oncologia ( Site 0405)
Porto Alegre, Rio Grande do Sul, Brazil
Clínica de Oncologia Reichow ( Site 0407)
Blumenau, Santa Catarina, Brazil
Centro de Investigación Oncológica del Norte ( Site 0504)
Antofagasta, Chile
James Lind Centro de Investigación del Cáncer ( Site 0502)
Temuco, Araucania, Chile
CIDO SpA-Oncology ( Site 0508)
Temuco, Araucania, Chile
Biocenter ( Site 0514)
Concepción, Biobio, Chile
FALP-UIDO ( Site 0505)
Santiago, Region M. de Santiago, Chile
Centro de Oncología de Precisión ( Site 0515)
Santiago, Region M. de Santiago, Chile
Bradfordhill ( Site 0510)
Santiago, Region M. de Santiago, Chile
ONCOCENTRO APYS-ACEREY ( Site 0503)
Viña del Mar, Valparaiso, Chile
Anhui Provincil Hospital South District-Respiratory Medicine Dept ( Site 2619)
Hefei, Anhui, China
Beijing Cancer hospital-Thoracic Cancer Department A ( Site 2602)
Beijing, Beijing Municipality, China
Showing 40 of 149 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.